Albumin Nanoparticles Co-Loaded with Dual Drugs for Enhanced Ferroptosis-Based Cancer Therapy through Modulating...

Area of Science:

• Biochemistry
• Cell Biology
• Nanomedicine

Background:

• Ferroptosis, a cell death pathway, is inhibited by lipid rafts on cell membranes.
• Sterol O-acyltransferase 1 (SOAT1), which stores cholesterol, is upregulated in tumors, hindering ferroptosis.
• Targeting cholesterol metabolism offers a novel approach for cancer therapy.

Purpose of the Study:

• To develop a nanoparticle system for codelivering a SOAT1 inhibitor and a ferroptosis inducer.
• To investigate the synergistic effect of inhibiting SOAT1 and inducing ferroptosis in cancer cells.
• To evaluate the potential of this strategy for combined chemotherapy and immunotherapy.

Main Methods:

• Human serum albumin nanoparticles (HSA@Aur&Ava) were engineered for codelivery of avasimibe (Ava) and auranofin (Aur).
• Ava inhibits SOAT1, disrupting lipid rafts by blocking cholesterol esterification.
• Aur induces ferroptosis by inhibiting thioredoxin reductase.

Main Results:

• The nanoparticles effectively disrupted lipid rafts and induced ferroptosis.
• Combined Ava and Aur demonstrated synergistic effects, enhancing lipid peroxide accumulation.
• The treatment activated an immune response via damage-associated molecular patterns (DAMPs), recruiting CD8+ T cells.

Conclusions:

• HSA@Aur&Ava nanoparticles show significant antitumor efficacy through combined chemotherapy and immunotherapy.
• Targeting cholesterol metabolism via SOAT1 inhibition is a promising strategy to enhance ferroptosis.
• This approach offers a novel insight into developing effective antitumor strategies.